Code of Federal Regulations: Containing a Codification of Documents of General Applicability and Future Effect as of December 31, 1948, with Ancillaries and IndexDivision of the Federal Register, the National Archives, 1998 Special edition of the Federal Register, containing a codification of documents of general applicability and future effect ... with ancillaries. |
No grāmatas satura
6.–10. rezultāts no 100.
18. lappuse
... preparation contains not more than 50 milligrams of pamabrom per dosage unit . ( v ) The preparation is labeled with adequate directions for use in the tem- porary relief of the minor pains and discomforts that may occur a few days ...
... preparation contains not more than 50 milligrams of pamabrom per dosage unit . ( v ) The preparation is labeled with adequate directions for use in the tem- porary relief of the minor pains and discomforts that may occur a few days ...
19. lappuse
... preparation meet their professed standards of iden- tity , strength , quality , and purity . ( iii ) If the preparation is a new drug , an application pursuant to section 505 ( b ) of the act is approved for it . ( iv ) The preparation ...
... preparation meet their professed standards of iden- tity , strength , quality , and purity . ( iii ) If the preparation is a new drug , an application pursuant to section 505 ( b ) of the act is approved for it . ( iv ) The preparation ...
20. lappuse
... preparation contains not more than 1 percent of biphenamine hydrochloride . ( v ) The preparation is labeled with adequate directions for use for the tem- porary relief of itching and scaling due to dandruff . ( vi ) The label bears a ...
... preparation contains not more than 1 percent of biphenamine hydrochloride . ( v ) The preparation is labeled with adequate directions for use for the tem- porary relief of itching and scaling due to dandruff . ( vi ) The label bears a ...
211. lappuse
... preparations de- scribed in this paragraph contain one or more nonnarcotic active medicinal ingredients in sufficient proportion to confer upon the preparation valuable medicinal qualities other than those possessed by the narcotic drug ...
... preparations de- scribed in this paragraph contain one or more nonnarcotic active medicinal ingredients in sufficient proportion to confer upon the preparation valuable medicinal qualities other than those possessed by the narcotic drug ...
292. lappuse
... preparation is used persists or if a rash or irritation develops , dis- continue use and consult physician . ANTIHISTAMINICS FOR EXTERNAL USE ( EXCEPT PREPARATIONS FOR OPHTHALMIC USE ) . Caution - Do not use in the eyes . If the ...
... preparation is used persists or if a rash or irritation develops , dis- continue use and consult physician . ANTIHISTAMINICS FOR EXTERNAL USE ( EXCEPT PREPARATIONS FOR OPHTHALMIC USE ) . Caution - Do not use in the eyes . If the ...
Saturs
279 | |
285 | |
290 | |
299 | |
310 | |
331 | |
339 | |
340 | |
223 | |
236 | |
238 | |
239 | |
240 | |
256 | |
257 | |
262 | |
263 | |
265 | |
270 | |
275 | |
351 | |
483 | |
588 | |
593 | |
696 | |
699 | |
761 | |
826 | |
865 | |
890 | |
911 | |
949 | |
Citi izdevumi - Skatīt visu
Bieži izmantoti vārdi un frāzes
abbre abbreviated application abbreviated new drug acid active ingredient adverse drug experience agency amended antibiotic application or abbreviated bacitracin bioavailability bioequivalence cation Center for Drug certification chapter clinical hold clinical investigation conducted control number copy Cosmetic Act digoxin dosage form dose Drug Administration drug application Drug Evaluation drug prod drug product Drug products containing drug substance Evaluation and Research Federal Food Food and Drug graph gredients hearing hydrochloride identified information requirements ap insulin intended inves investigational new drug labeling manufacturer marketing meet ment milligrams milliliters misbranded neomycin notice oral dosage orphan drug OTC drug product package paragraph percent person plication polymyxin proposed protocol recognized as safe reference listed drug request safe and effective safety section 502 Sodium sponsor statement submission Subpart sulfate tained tigational tion tive treatment treatment IND vestigational viated warning